by
Lynn Shapiro, Writer | January 14, 2009
There is a significant unmet medical need for viable reconstructive alternatives for women who undergo partial mastectomy as part of their breast cancer treatment, Cytori officials note.
An estimated 375,000 patients in Europe are diagnosed each year with breast cancer, of which approximately 75% are eligible to undergo partial mastectomy. To pursue this market, Cytori is conducting a 70-patient, multi-center post-marketing study using the Celution System output for breast reconstruction in women who have undergone partial mastectomy.
Translational Medicine
The medical community is rapidly exploring the potential of adult stem cell-based therapies, as evidenced by the growing number of positive clinical outcomes being reported. The Celution System has the opportunity to serve as the technology of choice for accessing adult stem and regenerative cells, as it allows surgeons to work with their patient's own cells, eliminating the risk of rejection or disease transmission. In addition, the device enables the cells to be processed and re-implanted in the same surgical procedure.
(In Japan, seven clinical studies using adipose-derived stem and regenerative cells have been approved by local ethical committees to be performed at academic university hospitals. These studies include vocal cord paralysis, chronic liver insufficiency, cirrhosis, radiation injury, and urinary incontinence.)
StemSource Cell Bank
A StemSource Cell Bank will allow hospitals, stem cell storage companies, or tissue banking labs to process and cryopreserve a patient's own adipose-derived stem and regenerative cells when the cells are younger and more viable. StemSource cell banking services coupled with the real time Celution clinical cell therapy may ultimately allow hospitals to provide a broad array of regenerative medicine services to patients, Cytori says.
About Cytori
Cytori's (NASDAQ: CYTX) goal is to be the global leader in regenerative medicine. The company is dedicated to providing patients with new options for reconstructive surgery, developing treatments for cardiovascular disease, and banking patients' adult stem and regenerative cells.
Clinical trials are ongoing in cardiovascular disease and planned for spinal disc degeneration, gastrointestinal disorders, and other unmet medical needs, the company says.
Back to HCB News
